Retrophin Inc (NASDAQ:RTRX) has been given a consensus recommendation of “Hold” by the six brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $44.00.
Several research analysts have recently commented on the company. Zacks Investment Research downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a report on Friday, October 6th.
A number of large investors have recently made changes to their positions in RTRX. SG Americas Securities LLC increased its holdings in Retrophin by 1.8% during the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 146 shares during the period. Legal & General Group Plc increased its holdings in Retrophin by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 355 shares during the period. Trexquant Investment LP purchased a new position in Retrophin during the 3rd quarter valued at about $203,000. Dynamic Technology Lab Private Ltd purchased a new position in Retrophin during the 3rd quarter valued at about $212,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in Retrophin during the 3rd quarter valued at about $249,000.
Retrophin (RTRX) traded down $0.05 on Wednesday, hitting $24.70. The stock had a trading volume of 215,452 shares, compared to its average volume of 211,042. The stock has a market capitalization of $972.84, a P/E ratio of -16.36 and a beta of 0.96. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88. Retrophin has a 1 year low of $15.55 and a 1 year high of $26.44.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). The company had revenue of $40.34 million during the quarter, compared to analysts’ expectations of $40.51 million. Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The firm’s quarterly revenue was up 18.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) EPS. analysts expect that Retrophin will post -1.25 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Retrophin Inc (RTRX) PT at $44.00” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/13/analysts-set-retrophin-inc-rtrx-pt-at-44-00.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.